Shenzhen Zhongjia Biomedical Technology Co., Ltd. Shenzhen Zhongjia Biomedical Technology Co., Ltd.

Company News

Company News

Types and Typical Symptoms of MLD

2026-6-16

  MLD is mainly divided into three subtypes according to age of onset; the earlier the onset, the faster the disease progression and the worse the prognosis:

  Late-infantile type (most common, 50%~60%)

  Age of onset: 1-2 years old. Infants who were developing normally experience sudden developmental regression.

  Typical symptoms: unsteady gait, frequent falls, abnormal muscle tone (initially hypotonia, later progressing to spastic paralysis), speech regression, dysphagia, and impaired vision and hearing. Eventually seizures and a fully bedridden state may occur; most affected children do not survive to school age.

  Juvenile type (20%~30%)

  Age of onset: from 4 years old to adolescence.

  Typical symptoms: initially declining academic performance, behavioral abnormalities and inattention, gradually progressing to clumsiness, ataxia and limb spasticity. In the later stage, cognitive decline and swallowing dysfunction appear. Progression is relatively slow; most patients survive to around 20 years of age.

  Adult type (15%~20%)

  Age of onset: after 14 years old, or even in middle age.

  Typical symptoms: easily misdiagnosed as psychiatric disease. Patients show personality changes, depression, delusions and hallucinations, accompanied by limb weakness, ataxia and cognitive dysfunction. The disease follows a fluctuating progressive course with a survival of 20-30 years after onset.


Related News

  • Focus on MLD: Why Should This Rare Leukodystrophy Be Seen Earlier?

    2026-10-23

  • Can Alzheimer’s Risk Be Reduced? WHO Guidance Highlights Modifiable Dementia Risk Factors

    2026-9-28

  • Alzheimer's Treatment Advances: From Amyloid to Tau Multi-Target Research

    2026-9-28

  • New Progress in Early Alzheimer's Screening: Blood Tests Become an Important Research Direction

    2026-9-28

  • Great News! Another Zhongjia Medium Gets FDA DMF Filing

    2026-7-23